Tuberous Sclerosis Complex 1: An Epithelial Tumor Suppressor Essential to Prevent Spontaneous Prostate Cancer in Aged Mice

Raleigh D. Kladney1, Robert D. Cardiff5, David J. Kwiatkowski6, Gary G. Chiang7, Jason D. Weber1, Jeffrey M. Arbeit2,3,4, and Zhi Hong Lu2

Abstract

The phosphoinositide 3-kinase (PI3K) pathway regulates mammalian cell growth, survival, and motility and plays a major pathogenetic role in human prostate cancer (PCa). However, the oncogenic contributions downstream of the PI3K pathway made by mammalian target of rapamycin complex 1 (mTORC1)–mediated cell growth signal transduction in PCa have yet to be elucidated in detail. Here, we engineered constitutive mTORC1 activation in prostate epithelium by a conditional genetic deletion of tuberous sclerosis complex 1 (Tsc1), a potent negative regulator of mTORC1 signaling. Epithelial inactivation was not immediately tumorigenic, but Tsc1-deficient mice developed prostatic intraepithelial neoplasia (mPIN) in lateral and anterior prostates by 6 months of age, with increasing disease penetrance over time. Lateral prostate lesions in 16- to 22-month-old mutant mice progressed to two types of more advanced lesions, adenomatous gland forming lesion (Type 1) and atypical glands embedded in massively expanded reactive stroma (Type 2). Both Type 1 and Type 2 lesions contained multiple foci of microinvasive carcinoma. Epithelial neoplastic and atypical stromal lesions persisted despite 4 weeks of RAD001 chemotherapy. Rapalogue resistance was not due to AKT or extracellular signal–regulated kinase 1/2 activation. Expression of the homeobox gene Nkx3.1 was lost in Tsc1-deficient mPIN, and it cooperated with TSC1 loss in mPIN initiation in doubly mutant Tsc1/Nkx3.1 prostatic epithelial knockout mice. Thus, TSC1 inactivation distal to PI3K and AKT activation is sufficient to activate a molecular signaling cascade producing prostatic neoplasia and focal carcinogenesis. Cancer Res; 70(21); 8937–47. ©2010 AACR.

Introduction

Human prostate cancer (PCa) develops via multistage progression over a particularly long duration, associated with progressive accumulation of mutations and epigenetic alterations in oncogenes and tumor suppressors. The phosphoinositide 3-kinase (PI3K) pathway, which plays a major role in mammalian cell growth, survival, and motility, has emerged as a central regulator of human PCa. PCa PI3K pathway activation occurs via complete loss or haploinsufficiency in the suppressor of this pathway, phosphatase and tensin homologue deleted on chromosome 10 (PTEN), occurring in 20% to 70% of primary PCa and 30% to 80% of locally advanced and metastatic disease (1–3). Conditional deletion of the Pten gene in mouse prostate epithelium leads to invasive prostate adenocarcinoma (4), further supporting a key etiologic role of PI3K signaling in prostate neoplasia.

Among many proposed functions, the PI3K pathway promotes mammalian cell growth through constitutive activation of the AKT and mammalian target of rapamycin complex 1 (mTORC1) protein kinase signaling module. AKT activates mTORC1 in part through inhibitory phosphorylation of tuberous sclerosis complex 2 (TSC2; refs. 5–8). TSC2 heterodimerizes with TSC1, and heterodimer formation is required for both TSC2 protein stabilization and activation of GTPase (GAP) function on the small G protein, RHEB (9–12). GTP-RHEB is a direct activator of mTORC1, which in turn promotes ribosomal biogenesis, enhances protein and lipid synthesis, and prevents autophagy (reviewed in ref. 13).

Like upstream PTEN, TSC1 and TSC2 are tumor suppressors. Originally identified through their involvement in an inherited tumor syndrome affecting multiple soft tissues of mesenchymal origin (14), TSC1 and TSC2 genetic alterations have been identified in sporadic carcinomas of the bladder and head and neck, implicating the genes as broad spectrum human tumor suppressors (15–18). Nonetheless, TSC1/TSC2 seems to be much less commonly involved in human cancer than PTEN or LKB1. There is limited data on mutation or...
deletion of *TSC1* or *TSC2* in human PCAs, but strong evidence suggests TSC1/2 functional inactivation in this disease. In addition to AKT, TSC1/2 GAP activity toward RHEB is inhibited by extracellular signal-regulated kinase 1/2 (ERK1/2) pathway phosphorylation (19, 20). Moreover, loss of LKB1, seen in advanced PCAs, produces reduced AMPK activity, diminution of TSC1/TSC2 suppression, and consequent mTORC1 activation (21). As AKT, ERK1/2, and AMPK all phosphorylate TSC2 at distinct sites (21, 22), multiple aberrant signaling pathways may cause combinatorial TSC1/2 inactivation, enabling gradations of mTORC1 dysregulation during human PCA progression.

To date, the direct effect of TSC1/2 inactivation on PCA pathogenesis has not been tested in a preclinical model. Induction of preneoplastic hyperplasia without neoplastic progression in transgenic mouse prostates overexpressing RHEB suggested that either an insufficient level of mTORC1 activation was attained by RHEB overexpression, or mTORC1 activation alone was insufficient to produce carcinogenesis (23).

Here, we tested the role of persistent constitutive mTORC1 pathway activation in prostate carcinogenesis using a novel mouse model of TSC1 deletion in prostate epithelium. Homozygous *Tsc1* loss of function and consequent mTORC1 hyperactivation produced two histologic and molecular forms of spontaneous prostate carcinogenesis in aged mice, both associated with precursor (mouse prostatic intraepithelial neoplasia) mPIN lesions. Thus, TSC1/2-mTORC1 pathway activation alone is sufficient to initiate prostate neoplasia and facilitate malignant transformation.

## Materials and Methods

### Mouse experiments

All animal work was approved by the Washington University Animal Studies Committee. Mice harboring a loxP-flanked *Tsc1* allele (*Tscf*φ) and *Pb-Cre4* (*PbCre*) transgenic mice have been described previously (4, 14), and the expression of the *Pb-Cre4* transgene has been shown to be specific for prostate epithelial cells (4). *PbCre* males (*FVB/n*) and *Tscf*φ females (mixed BALB/c, C57BL/6, and 129/SyJae) were intercrossed in a two-step breeding strategy to generate the target *PbCre*–*Tscφ* genotype. The mixed genetic background of the mice could underlie differences in tumor phenotype, i.e., penetrance and time of onset of tumor development between our study and that of others in the literature. Germine *Nkx3.1* knockout mice used to generate *Pb-Cre*-*Tscf*φ/*Nkx3.1* (*Nk3.1*ko/ko) have been described previously (24). In the chemotherapy trial, six *PbCre*–*Tscφ* mice (16–22 month of age) were treated with 7.5 μg/g of RAD001 (Novartis Corp.) by gavage three times per week for 4 weeks. A cohort of 22-month-old mice was castrated, and genitourinary tracts were removed 4 weeks later.

### Tissue harvest and histology

Male genitourinary tracts were harvested from formalin-perfused mice, fixed by microwave, and dissected following a standard procedure (25, 26). The isolated anterior prostates (AP) and urethra containing dorsal, lateral, and ventral prostates were processed through graded alcohols and xylenes and embedded in paraffin so that coronal/sagittal (APs) and transverse (urethra) sections were obtained. For histology, 5-μm sections were stained with H&E, and images were obtained with a DPT70 color Bayer mosaic digital camera (Olympus America) with MicroSuite Biological Suite v5 software (Olympus Soft Imaging Solutions).

### Immunofluorescence and immunohistochemistry

Sections were deparaffinized, rehydrated, washed in PBS (pH 7.4), and blocked with serum-free Dako Protein Block (Dako North America). Antigen retrieval was performed in 1x Reveal Decloaker reagent (pH6.0; Biocare Medical) with a pressure cooker. Primary antibodies were diluted in Dako Antibody Diluent. Primary antibodies included rabbit anti-α-SMA (1:500, Abcam), rabbit anti-desmin (1:250 IF; 1:4,000 IHC, Abcam), rat anti-cytokeratin 8 (1:200, Cell Signaling Technology), rabbit anti-phosphorylated AKTS473 (1:250, Cell Signaling Technology), rabbit anti-phosphorylated ERK1/2 (1:200/200/200/200/200, 1:100, Cell Signaling Technology), rabbit anti-phosphorylated ERK1/2 (1:200/200/200/200/200, 1:100, Cell Signaling Technology), rabbit anti- Ki67 (1:2,000, Vector Labs), and rabbit anti-phosphorylated S6K (1:50, 1:100, Cell Signaling Technology). The slides were incubated with corresponding secondary antibodies conjugated with Alexa Fluor 488 and Alexa Fluor 594 (1:400; Invitrogen) and counterstained for nuclei with SlowFade Gold Antifade mounting reagent with 4′,6-diamidino-2-phenylindole (Invitrogen). Fluorescence microscope images were collected using a Soft Imaging Solutions VII digital camera with MicroSuite Biological Suite software (Olympus). Immunohistochemical staining was carried out following our previously published protocol (27).

### Immunoblotting

Snap-frozen prostate tissues were homogenized in radioimmunoprecipitation assay buffer (1× PBS, 1% Nonidet-P40, 1% sodium deoxycholate, 0.1% SDS, 1 mmol/L EDTA, and 1% Triton X-100) supplemented with Protease Inhibitor Cocktail (1:50, Sigma-Aldrich), 5 mmol/L NaF, and Phosphatase Inhibitor Cocktail 1 and 2 (1:50, Sigma-Aldrich). Protein lysates (100 μg) were separated on polyacrylamide gels by electrophoresis and transferred to polyvinylidene difluoride membranes. Membranes were blocked in TBS (pH 7.6) containing 0.5% Tween 20 (TBST) and 10% nonfat dry milk, briefly washed in wash buffer (0.5% nonfat dry milk in TBST) and incubated in wash buffer containing rabbit antibodies for TSC1, phosphorylated S6K (T389), S6K, phosphorylated 4E-BP1 (S235/236), ribosomal protein S6, phosphorylated eIF4G (S1198), eIF4G, phosphorylated AKT (S473), AKT, phosphorylated ERK1/2 (T200/Y204), ERK1/2 (all 1:1,000, Cell Signaling Technology), and a rabbit polyclonal antibody for β-tubulin (1:35,000, Abcam). Membranes were washed once with high-salt buffer (TBST containing 0.5 mol/L NaCl and 0.5% nonfat dry milk), two times with wash buffer, and incubated in wash buffer with goat anti-rabbit IgG-horseradish peroxidase conjugate (1:1,000, Santa Cruz) for 30 minutes. After one wash with high-salt buffer and three times with wash buffer, peroxidase activity was revealed by...
enhanced chemiluminescence using ECL Plus (GE Healthcare) and imaged using a Chemidoc XRS imaging system with Quantity One one-dimensional analysis software (Bio-Rad).

Statistical analysis

Data were expressed as the mean ± SD, and statistical significance was determined using two-tailed unpaired Student’s t test, Mann-Whitney U test, χ² test, or one-way ANOVA test followed by Bonferroni’s multiple tests using GraphPad Prism software (GraphPad Prism).

Results

Tsc1 inactivation in mouse prostate epithelium induced constitutive mTORC1 activation

Consistent with conditional gene inactivation, TSC1 protein levels were drastically reduced in lateral prostates (LP) and APs of 5-month-old PbCre'Tsc1<sup>fl/fl</sup> mice (designated as Tsc1 KO) compared with Tsc1<sup>fl/fl</sup> (wild-type, WT) littermates but were similar to WT in heart, lung, liver, spleen, and testis (LP, Fig. 1A; AP and nonprostate, data not shown). Extracts from 5-month-old Tsc1 KO prostates exhibited elevated levels of phosphorylated S6<sup>S235/236</sup>, phosphorylated eIF4G<sup>S1108</sup>, and phosphorylated S6K<sup>T389</sup>, consistent with mTORC1 pathway activation, and diminution of phosphorylated AKT<sup>S473</sup>, evidence for concomitant mTORC2-negative feedback (LP, Fig. 1A; AP, data not shown). Phosphorylated S6<sup>S235/236</sup> was uniformly distributed in each TSC1 KO luminal epithelial cell, in contrast to sporadic activation in WT counterparts as shown by cytokeratin 8 (keratin-8) colocalization (Supplementary Fig. S1A; high-magnification views of the same fields are shown in Fig. 1B), indicating that Tsc1 inactivation in prostate luminal cells led to cell autonomous constitutive mTORC1 activation. Notably, there was neither histopathology nor evidence of mTORC1 activation in the stroma of Tsc1 KO mice at this age (see below).

Adult Tsc1 KO mice developed spontaneous prostate carcinogenesis

Necropsy and histopathologic examination of genitourinary tracts were performed on adult Tsc1 KO mice between 3 and 22 months of age (n = 45). Age-matched WT littermates were negative controls (n = 27). Prostates of Tsc1 KO mice up to 5 months of age did not show any morphologic or histologic abnormality (Fig. 1C, 3–5 months, n = 8) despite chronic mTORC1 activation. At 6 months of age, mutant mice began...
to develop mPIN in LP and AP sites (6–11 months, \( n = 11 \)) with disease penetrance increasing over time (12–15 months, \( n = 14 \)), reaching 100% in APs and 75% in LPs in the 16- to 22-month-old group (\( n = 12 \); henceforth called the aged group). Tsc1 KO AP and LP mPIN lesions were often multifocal consisting of markedly enlarged epithelial cells with nuclear atypia that partially or completely filled the glandular lumen (Supplementary Fig. S1B; high-magnification views of the same fields are shown in Fig. 1D). Seven of 12 aged mutant mice developed visible LP enlargement with two also showing cystic AP dilation (Supplementary Fig. S1C and D). Further analyses focused on the LP because those lesions progressed (Fig. 2A–D) in contrast to mPIN persistence in the AP.

LP tumor histology revealed complex, multicompartmental pathology (Supplementary Fig. S1D; Fig. 2A–D). There were two types of advanced lesions. One contained a marked accumulation of adenomatous glands, designated as Type 1 tumor pattern (Supplementary Fig. S1D, left; Fig. 2A). As Type 1 tumors contained multiple foci of epithelial cell microinvasion into reactive stroma (Fig. 2B, yellow arrowheads) or microvessels (data not shown), these lesions were designated as Type 1 cancers, which were detected in 4 of 12 mice of 16–22 months of age (33%). Type 2 lesions consisted of neoplastic epithelial cells with nuclear atypia arranged in glands with irregular borders and embedded in a massive accumulation of hyperplastic stroma (Supplementary Fig. S1D, right; Fig. 2C). Stromal abnormalities possessed two components. One was elongated and hypertrophic fibroblasts with nuclear enlargement, nucleolar prominence, and frequent mitotic figures, localized just beneath the basement membrane of atypical neoplastic glands (insets of Fig. 2D, green arrowheads). The second stromal component contained eosinophilic mature fibroblasts (Fig. 2C). Type 2 tumors also contained focal epithelial cell invasion (Fig. 2D, yellow arrowheads) and, as such, were designated Type 2 cancers, which were detected in 6 of 12 mice of 16 to 22 months of age (50%).

**Progressive proliferative activation during Tsc1 KO prostate carcinogenesis**

To further determine mechanisms of Tsc1 KO multistage carcinogenesis, we determined the level and localization of proliferating cells in knockout prostates during aging (Fig. 3). As expected, the Ki67 index in normal prostates was extremely low (1–2%). Preneoplastic Tsc1 KO prostates evidenced equivalently low proliferation (data not shown). Both AP and LP mPIN lesions displayed significant elevation (4.1–4.7%) compared with WT prostates, with Ki67(+) cells restricted to neoplastic epithelium (Fig. 3A, top right versus top left). There was a differential progression in Ki67 index and disparate tissue compartmental localization of proliferative cells between Type 1 (9.3%) and Type 2 (16.3%) cancers. Type 1 proliferating cells were restricted to the neoplastic and malignant epithelial cells, whereas there was increased proliferation in both stroma and neoplastic epithelium of Type 2 cancers (Fig. 3A, bottom left versus bottom right).

**Early-stage epithelial dysplasia, malignant transformation, and stromal remodeling in Tsc1 KO prostate carcinogenesis**

Next, we interrogated mPIN and Type 1 and Type 2 cancers with a panel of antibodies specific for prostate epithelial differentiation dysregulation (keratin-5, keratin-8, and...
E-cadherin), mTORC1 activation (phosphorylated S6), and stromal remodeling/activation (desmin and smooth muscle actin; Fig. 4; Supplementary Fig. S2). Keratin-5, a basal cell marker, was circumferentially localized around each WT prostate ductule (Fig. 4; Supplementary Fig. S2, K5/K8, WT). Keratin-5 expression was markedly attenuated and sporadically distributed within neoplastic cells of Tsc1 KO mPIN lesions, lost in Type 1 cancers, but sporadically upregulated in clusters of neoplastic and malignant epithelial cells of Type 2 malignancies (Fig. 4; Supplementary Fig. S2). E-cadherin, an epithelial cell-to-cell junction molecule, was uniformly present in WT epithelia as well as in Tsc1 KO mPIN neoplastic cells but was reduced or absent in expression in subsets of Type 1 and Type 2 cancer cells (Fig. 4; Supplementary Fig. S2, E-CAD/K8; data not shown) consistent with the invasive phenotype of these cells. The mPIN and Type 1 malignant epithelial cells uniformly exhibited mTORC1 activation (Fig. 4; Supplementary Fig. S2, P-S6/K8), indicating a Tsc1-deficient luminal epithelial origin. Type 1 malignant microinvasion was strikingly evident by dual phosphorylated S6 and K8 labeling. In contrast, phosphorylated S6 was markedly elevated in stromal cells of Type 2 tumors with areas of microinvasive K8(+) cells also expressing the mTORC1 marker (Supplementary Fig. S3). mPIN induced stromal remodeling evidenced by loss of desmin and α-smooth muscle actin expression in the fibromuscular layer encircling neoplastic glands (Fig. 4, Tsc1 KO mPIN, DES/K8, and SMA/K8). Similar to phosphorylated S6, tissue compartmental desmin distribution distinguished Type 1 and Type 2 cancers; desmin was absent in Type 1 lesions but was markedly upregulated in Type 2 cancer stroma (Fig. 4 and Supplementary Fig. S2). To test the possibility that the Type 2 stromal cells were derived from subsets of Type 2 microinvasive cells with reduced or absent E-cadherin expression through an epithelial-to-mesenchymal transition (EMT), we investigated expression of zinc finger protein Snail, an E-cadherin transcriptional repressor and a potent EMT inducer. Despite extensive efforts, we could not detect Snail upregulation in invading epithelial cells or in desmin (+) stromal cells, nor could we detect keratin-8/desmin colocalization in mPIN or either type of malignant tumor (data not shown).

**Tsc1 KO prostate lesions showed partial therapeutic responses to mTORC1 inhibitor RAD001**

To determine whether mTORC1 signaling was required for the prostate disease maintenance, six aged Tsc1 KO mice (16–22 months) were treated for 4 weeks with mTORC1 inhibitor RAD001 (everolimus), an orally bioavailable derivative of rapamycin. As expected, the treatment produced a marked mTORC1 pathway inhibition in testes (Supplementary Fig. S4, P-S6) and prostates (Fig. 5A, P-S6/K8). RAD001 induced a prominent antiproliferative effect in the testis (Supplementary Fig. S3, K67) but had no effect on the proliferation in the prostate lesions (Fig. 5A, K67/K8; data not shown). mPIN was persistent in both the APs (six of six; Fig. 5B, AP) and LPs with a subset of LP lesions containing additional desmin (+) stroma (five of six and three of six, respectively; Fig. 5B, LP). Morphologically, RAD001 decreased but did not eliminate the prevalence of atypical giant cell epithelium in mPIN or stromal lesions, whereas microinvasive adenocarcinoma was notably undetectable in LPs of the treated mice, implying that mPIN and Type 2 stromal lesions were more resistant to RAD001 than microinvasion. The regression of enlarged mPIN glands was often accompanied by stromal fibrosis (Fig. 5B). Whereas the rapamycin resistance of these lesions is compelling, an expanded study with larger cohorts will be needed for adequate testing of this hypothesis.

Inhibition of mTORC1/S6K pathway may abrogate S6K-mediated negative feedback on AKT and ERK1/2 activation, which has been linked to tumor cell rapalogue resistance (see Discussion). However, phosphorylation of AKT and ERK1/2 was similar between 15-month-old WT and Tsc1 KO mice by immunoblotting (Fig. 5C), indicating that mTORC1/S6K-mediated negative feedback was not elicited in prostates of aged mice. As a positive AKT activation control, LPs from a 2-month-old PbCre^Pten^fl/fl (Pten KO) mouse, as expected,
exhibited marked phosphorylated AKT immunofluorescence (Fig. 5D, P-AKT, Pten KO LP). In contrast, both untreated and RAD001-treated Tsc1 KO LP tumor cells showed similarly low-background phosphorylated AKT signal (Fig. 5D, P-AKT, Tsc1 KO LP, RAD001 versus Untreated). In addition, sporadic ERK1/2 activation was detected in stroma inflammatory cells of aged WT LPs and in both epithelial and stromal cells in Tsc1 KO mPIN lesions (Fig. 5D, P-ERK, WT LP Untreated versus Tsc1 KO LP Untreated). Importantly, RAD001 treatment did not change the levels of ERK phosphorylation in Tsc1 KO prostate tumors (Fig. 5D, Tsc1 KO LP, RAD001 versus Untreated). Together, our data suggested that activation of either mTORC2 or ERK was not responsible for the RAD001 resistance of Tsc1 KO prostate tumors.

Loss of Nkx3.1 protein expression occurred in Tsc1 KO carcinogenesis and played a cooperative role in the initiation of mPIN

As the prostate-specific tumor suppressor, homeobox protein Nkx3.1, is frequently downregulated in human and mouse PCas and loss of a single Nkx3.1 allele can cooperate with Pten loss of function in prostate carcinogenesis (28), we analyzed its protein expression in Tsc1 KO prostate carcinogenesis. As expected, WT prostate luminal cells showed abundant nuclear Nkx3.1 immunoreactivity, whereas age-matched Nkx3.1 KO counterparts lacked detectable staining (Fig. 6A, WT and Nkx3.1 KO). Nkx3.1 was present in morphologically normal Tsc1 KO luminal cells but undetectable in all mPINs and carcinomas (Tsc1...
KO mPIN, Fig. 6A; PCa, data not shown). Thus, NKX3.1 loss was associated with the onset of mPIN, a precursor event in Tsc1 KO prostate carcinogenesis. Remarkably, NKX3.1 immunoreactivity remained undetectable in RAD001-treated lesions (Fig. 6A, Tsc1 KO LP, RAD001), showing that NKX3.1 loss in neoplastic cells was not regulated by RAD001-mediated mTORC1 inactivation. Thus, it is possible that loss of NKX3.1 may provide the mTORC1-independent growth signal to Tsc1 KO tumors treated with RAD001.

To test a functional role for NKX3.1 in Tsc1 KO prostate carcinogenesis, disease incidence and severity were tested in mice homozygous for a germline Nkx3.1 deletion in the Tsc1 KO background (designated as DKO for double KO) compared with Nkx3.1 and Tsc1 single KO mice. A significantly higher proportion of 4- to 5-month-old DKO mice (eight of nine) developed mPIN in APs (Fig. 6B, 4–5 months, AP) than did either Nkx3.1 (three of seven) or Tsc1 single KO (zero of seven) mice. Unlike the low-grade mPINs exhibited by the Nkx3.1 KO mice (Fig. 6C, 5 months, AP, Nkx3.1 KO, inset), DKO mPIN cells displayed enlarged cytoplasm and nuclear atypia (Fig. 6C, 5 months, AP, DKO, inset). Furthermore, a significantly higher proportion (six of seven) of 7- to 8-month-old DKO mice developed LP mPIN lesions than age-matched Nkx3.1 KO (zero of five) and Tsc1KO (one of five) mice (Fig. 6B, 7–11 months, LP). DKO LP mPIN contained Tsc1 KO characteristic atypical cells (Fig. 6C, 8 months, LP, DKO, inset). As the DKO mice further aged, Type 1 and Type 2 cancers developed, albeit at similar frequencies compared with Tsc1 KO counterparts with no evidence of metastatic disease development (data not shown). Thus, combinatorial Nkx3.1 and Tsc1 loss-of-function accelerated prostatic neoplastic initiation but failed to affect malignant conversion.

Figure 5. Prostate lesion persistence in RAD001-treated Tsc1 KO mice. A, marked reduction in P-S6 immunoreactivity in Tsc1 KO prostate AP glands treated with 4 wk RAD001, without significant effect on Ki67 index. B, mPIN and stromal hyperplastic persistence in RAD001-treated Tsc1 KO prostates. C, LPs of 15-mo-old WT (n = 2) and Tsc1 KO (n = 3) mice displayed similar level of AKT and ERK1/2 phosphorylation. D, the LP glands of a 4-mo-old PbCre PTEN floxed mouse exhibited drastically activated AKT (left). RAD001 treatment did not activate AKT (P-AKT, Tsc1 KO LP untreated versus RAD001) or ERK1/2 (P-ERK, Tsc1 KO LP untreated versus RAD001) in Tsc1 KO prostate mPIN lesions. A, bars, 200 μm (left two panels) and 100 μm (right two panels). B, bars, 200 μm (left and left middle panels) and 100 μm (right middle and right panels). D, bar, 100 μm.
**Tsc1 KO** lesions display differential cell type androgen dependency

The resistance of mPIN lesions during chronic RAD001 therapy and the persistent loss of NKX3.1 expression in de novo and RAD001-treated mice led us to explore androgen dependency of Tsc1 KO prostate neoplasias. A small group of three Tsc1 KO, one Tsc1:Nkx3.1 DKO, and one control mouse was castrated, and genitourinary tracts were analyzed by histopathology and immunofluorescence. Multiple mPIN lesions persisted in both the lateral and anterior prostates (Supplementary Fig. S5; Supplementary Table S1). These lesions also retained mTORC1 activation (Supplementary Fig. S5). Type 2 lesions, confined to the LP, underwent marked regression (Supplementary Fig. S5, Type 2 stroma reversion). Even massive lesions evidenced extensive necrosis localized to in the stroma. High power views revealed marked inflammatory cell infiltration, stromal cell drop out, and fibrosis (Supplementary Fig. S5). Castrate desmin expression response was heterogeneous, sporadic in lesions with necrosis and stromal infiltration, and diffuse in a small persistent tumor that also displayed both epithelial and stromal mTORC1 hyperactivation. These data, along with both the progression kinetics wherein epithelial mPIN developed before stromal alterations and the mPIN persistence, suggest, but do not prove, that Tsc1 KO epithelial neoplasia was predominant and that stroma lesions were likely secondary to chronic epithelial activation.

**Discussion**

Here, we showed multistage prostate carcinogenesis in mice with prostate luminal cell Tsc1 deletion. As expected, Tsc1 deletion produced mTORC1 activation in luminal prostate epithelial cells of young male mice. However, prostate neoplasia development and microinvasive cancer required a prolonged latency. mPIN onset was associated with NKX3.1 loss of expression, and the functional importance of this secondary event was supported by disease acceleration in Nkx3.1:Tsc1 DKO mice. Interestingly, TSC1 loss-of-function produced two distinct histologic malignancies, one predominantly glandular and the other associated with pronounced stromal activation and hyperplasia. These data
show that TSC1 loss-of-function produces a form of neoplastic progression and malignant conversion remarkably similar to the kinetics and molecular biology of human disease.

PI3K-mTORC1 pathway perturbations have been extensively investigated in prostate luminal epithelial cells through conditional PTEN (4, 29) or TSC1 (current study) loss of function and through targeted AKT (30) or RHEB (23) gain of function, offering the opportunity for a comparison of pathway level perturbation on PCA pathogenesis. Whereas Pten biallelic deletion caused invasive PCa, expression of constitutively activated myristoylated AKT (MPAKT) produced mPIN albeit with a more severe phenotype in the C57BL/6 versus FVB genetic background (31). Consistent with the notion that AKT activation alone did not possess all malignant activities of PTEN inactivation, PTEN loss activated c-Jun NH2 terminal kinase along with AKT in human PCa and the two pathways synergized in cell transformation (32).

Nonetheless, given the many downstream substrates of AKT, it is surprising that AKT activation had a more benign prostate phenotype than loss of TSC1, which represents only a single AKT target. This may reflect recruitment of additional TSC1/TSC2 functions in response to AKT activation. It is also surprising that RHEB overexpression, the canonical TSC1/TSC2 target, produced only preneoplastic epithelial hyperplasia in mice, despite constitutive mTORC1 activation (23). Whether the absence of malignant transformation in the RHEB model was due to insufficient transgene expression to fully activate mTORC1 or was indicative of potential RHEB-independent functions of TSC1/2 is uncertain.

The stochastic and delayed appearance of mPIN in prostatic Tsc1 KO mice suggests a requirement for spontaneous secondary genetic or epigenetic alterations for neoplastic induction. We showed a tight correlation between loss of NKX3.1 expression genetic or epigenetic alterations for neoplastic induction. Tsc1 KO mice fully activate mTORC1 or was indicative of potential RHEB model was due to insufficient transgene expression to fully activate mTORC1 or was indicative of potential RHEB-independent functions of TSC1/2 is uncertain.

The stochastic and delayed appearance of mPIN in prostatic Tsc1 KO mice suggests a requirement for spontaneous secondary genetic or epigenetic alterations for neoplastic induction. We showed a tight correlation between loss of NKX3.1 expression genetic or epigenetic alterations for neoplastic induction. Tsc1 KO mice fully activate mTORC1 or was indicative of potential RHEB model was due to insufficient transgene expression to fully activate mTORC1 or was indicative of potential RHEB-independent functions of TSC1/2 is uncertain.

Nonetheless, given the many downstream substrates of AKT, it is surprising that AKT activation had a more benign prostate phenotype than loss of TSC1, which represents only a single AKT target. This may reflect recruitment of additional TSC1/TSC2 functions in response to AKT activation. It is also surprising that RHEB overexpression, the canonical TSC1/TSC2 target, produced only preneoplastic epithelial hyperplasia in mice, despite constitutive mTORC1 activation (23). Whether the absence of malignant transformation in the RHEB model was due to insufficient transgene expression to fully activate mTORC1 or was indicative of potential RHEB-independent functions of TSC1/2 is uncertain.

The stochastic and delayed appearance of mPIN in prostatic Tsc1 KO mice suggests a requirement for spontaneous secondary genetic or epigenetic alterations for neoplastic induction. We showed a tight correlation between loss of NKX3.1 expression genetic or epigenetic alterations for neoplastic induction. Tsc1 KO mice fully activate mTORC1 or was indicative of potential RHEB model was due to insufficient transgene expression to fully activate mTORC1 or was indicative of potential RHEB-independent functions of TSC1/2 is uncertain.

Nonetheless, given the many downstream substrates of AKT, it is surprising that AKT activation had a more benign prostate phenotype than loss of TSC1, which represents only a single AKT target. This may reflect recruitment of additional TSC1/TSC2 functions in response to AKT activation. It is also surprising that RHEB overexpression, the canonical TSC1/TSC2 target, produced only preneoplastic epithelial hyperplasia in mice, despite constitutive mTORC1 activation (23). Whether the absence of malignant transformation in the RHEB model was due to insufficient transgene expression to fully activate mTORC1 or was indicative of potential RHEB-independent functions of TSC1/2 is uncertain.

The stochastic and delayed appearance of mPIN in prostatic Tsc1 KO mice suggests a requirement for spontaneous secondary genetic or epigenetic alterations for neoplastic induction. We showed a tight correlation between loss of NKX3.1 expression genetic or epigenetic alterations for neoplastic induction. Tsc1 KO mice fully activate mTORC1 or was indicative of potential RHEB model was due to insufficient transgene expression to fully activate mTORC1 or was indicative of potential RHEB-independent functions of TSC1/2 is uncertain.
in which TSC1 or TSC2 loss alone has been shown to progress to full carcinoma without other engineered genetic events. Our data suggest that loss of Nkx3.1 expression, as discussed above, seems to be the key step in this progression.

In conclusion, we show that the TSC1/TSC2 protein complex functions as a critical cell growth checkpoint in prostate luminal epithelial cells, such that isolated loss of TSC1 leads to spontaneous PCa formation. This observation expands our concepts of PI3K pathway function in PCa development but generates new questions about the differential tumorigenic phenotypes produced by downstream pathway component dysregulation. The incomplete rapalogue sensitivity of mTORC1 (48), the parallel signaling of mTORC2 (reviewed in ref. 49), and the partial rapalogue efficacy in Tsc1 KO prostate neoplasia motivate further study of more potent mTOR catalytic site or alternative PI3K inhibitors in treating PCs with PI3K pathway activation (50).

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Rebecca Soin for mouse husbandry, Novartis for the gift of RAD001, and Leonard B. Maggi, Jr., for the critical reading of the manuscript.

Grant Support

NIH grants R01 CA10101 and R01 CA120436, National Cancer Institute grant 1P01CA120964-01A1, and the Beatrice Roe fund for Urological Research. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 05/10/2010; revised 08/16/2010; accepted 09/01/2010; published OnlineFirst 10/12/2010.

References


Tuberous Sclerosis Complex 1: An Epithelial Tumor Suppressor Essential to Prevent Spontaneous Prostate Cancer in Aged Mice

Raleigh D. Kladney, Robert D. Cardiff, David J. Kwiatkowski, et al.

Cancer Res 2010;70:8937-8947. Published OnlineFirst October 12, 2010.

Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-10-1646

Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2010/10/11/0008-5472.CAN-10-1646.DC1

This article cites 50 articles, 20 of which you can access for free at:
http://cancerres.aacrjournals.org/content/70/21/8937.full#ref-list-1

This article has been cited by 4 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/70/21/8937.full#related-urls

Sign up to receive free email-alerts related to this article or journal.
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.